Which medications with uncertain efficacy have been used to treat immune thrombocytopenic purpura (ITP)?

Updated: Jun 28, 2019
  • Author: Craig M Kessler, MD, MACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

For many years, the only treatment options after corticosteroids, IV RhIG, IVIG, and rituximab were cyclophosphamide, azathioprine, and danazol. Interventions with decreased certain efficacy and with conflicting reports in the literature include alemtuzumab, azathioprine, danazol, dapsone, vinblastine, vincristine, ascorbic acid, colchicine, and interferon alfa. [52, 53, 54, 55, 56, 57, 58]  In the past decade, thrombopoietin (TPO) receptor agonists have entered clinical practice as second-line agents. Three of these agents are currently available: romiplostin (Nplate), eltrombopag (Promacta), and avatrombopag (Doptelet).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!